CORRECTED-Celgene to stop blood cancer trial due to higher death rates
(Corrects paragraph 1 to say the drug was compared to another drug and not a placebo)
July 18 (Reuters) - Celgene Corp said it will stop a late-stage trial of its blood cancer drug Revlimid after it observed a higher number of deaths in patients taking the drug compared to those on another treatment.
The trial was placed on a clinical hold by the U.S. Food and Drug Administration on July 12, Celgene said. The study was testing the drug in previously untreated, elderly patients with B-cell chronic lymphocytic leukemia.
(Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)
- Citing security threat, Obama expands U.S. role fighting Ebola
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Stocks end higher on bet Fed won't change rate stance
- U.S. general says cannot rule out larger ground role in Iraq